Form 4: BridgeBio Pharma's President and COO, Thomas Trimarchi, Reports Stock and Option Awards

Thomas Trimarchi, President and COO of BridgeBio Pharma, reports the acquisition of restricted stock units and stock options.

Summary

• On August 6, 2024, Thomas Trimarchi, President and COO of BridgeBio Pharma, reported the acquisition of 19,003 restricted stock units (RSUs) and 3,160 stock options.
• The RSUs were granted under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan.
• The RSUs and stock options vest in 16 quarterly installments beginning on August 16, 2024, contingent upon continued service with the Issuer or its subsidiaries.
• The exercise price of the stock options is $24.87.
• Following the reported transactions, Trimarchi beneficially owns 413,859 shares of Common Stock and 3,160 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning management interests with shareholders. There are no indications of negative events or concerns.

Positives

• The grant of RSUs and stock options aligns the executive's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the President and COO.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.

Industry Context

Stock and option awards are a common practice in the pharmaceutical industry to incentivize and retain key executives. These awards align management's interests with those of shareholders, encouraging long-term value creation.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices among publicly traded biopharmaceutical companies.
• Companies like Amgen, Gilead, and Regeneron routinely use similar equity-based compensation to incentivize their executives.
• The vesting schedules, typically over a 4-year period, are also in line with industry norms to ensure long-term commitment.

Stakeholder Impact

• The grant of equity-based compensation can positively impact shareholders by aligning management's interests with long-term company performance.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates